Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells.
Jean A BernatchezMichael CosteSungjun BeckGrace A WellsLucas A LunaAlex E ClarkZhe ZhuDavid HechtJeremy N RichChristal D SohlByron W PurseJair L Siqueira-NetoPublished in: Viruses (2019)
Zika virus (ZIKV), an emerging flavivirus that causes neurodevelopmental impairment to fetuses and has been linked to Guillain-Barré syndrome continues to threaten global health due to the absence of targeted prophylaxis or treatment. Nucleoside analogues are good examples of efficient anti-viral inhibitors, and prodrug strategies using phosphate masking groups (ProTides) have been employed to improve the bioavailability of ribonucleoside analogues. Here, we synthesized and tested a small library of 13 ProTides against ZIKV in human neural stem cells. Strong activity was observed for 2'-C-methyluridine and 2'-C-ethynyluridine ProTides with an aryloxyl phosphoramidate masking group. Substitution of a 2-(methylthio) ethyl phosphoramidate for the aryloxyl phosphoramidate ProTide group of 2'-C-methyluridine completely abolished antiviral activity of the compound. The aryloxyl phosphoramidate ProTide of 2'-C-methyluridine outperformed the hepatitis C virus (HCV) drug sofosbuvir in suppression of viral titers and protection from cytopathic effect, while the former compound's triphosphate active metabolite was better incorporated by purified ZIKV NS5 polymerase over time. These findings suggest both a nucleobase and ProTide group bias for the anti-ZIKV activity of nucleoside analogue ProTides in a disease-relevant cell model.
Keyphrases
- emergency department
- zika virus
- hepatitis c virus
- dengue virus
- neural stem cells
- aedes aegypti
- endothelial cells
- global health
- sars cov
- human immunodeficiency virus
- public health
- molecular docking
- single cell
- cell therapy
- mesenchymal stem cells
- case report
- preterm birth
- ionic liquid
- electronic health record
- congenital heart disease
- drug release